drugset

drugset / Trial / NCT00761852

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

NCT00761852 ↗

Phase 2/3 Completed 30 enrolled Brigham and Women's Hospital Eli Lilly and Company · collab

RandomizedCrossoverQuadruple-blindBasic science

Summary

Ruboxistaurin is being tested to see if it is effective in treating certain diabetic complications, such as diseases of the blood vessels.

Timeline

Start: 1999-05
Primary completion: 2007-10
Completion: 2007-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ruboxistaurin	Small molecule	32 mg	—

Indications